Please login to the form below

Not currently logged in
Email:
Password:

GSK plans to sell off non-key OTC products

GlaxoSmithKline is to sell off several over-the-counter brands, including weight-management drug Alli, as part of efforts to streamline its Consumer Healthcare business

GlaxoSmithKline (GSK) is to sell off several over-the-counter brands, including weight-management drug Alli, as part of efforts to streamline its Consumer Healthcare business.

The company said the products it intends to divest had sales of around £500m for 2010 - around 10 per cent of total turnover for GSK's Consumer Healthcare division for the year.

Other GSK brands to be sold off include the painkillers Solpadeine, BC and Goody's; vitamin supplement Abtei; and Lactacyd for feminine hygiene.

In a statement, GSK said the lines lack 'sufficient critical mass' with the company looking to focus on leading brands such as Sensodyne, Panadol and Horlicks over its three priority categories in its Consumer Healthcare division – oral health, wellness/OTC and Nutrition.

"Consumer Healthcare is a key growth driver for GSK," said Andrew Witty, CEO of GSK. "But it is important that we focus this business around product categories, brands and markets where we have most depth and competitive advantage, with the best prospects for strong growth."

Product divestment is intended to happen by late 2011, with GSK to talk to interested parties over the next few weeks.

Contact:

Phone:

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
eyeforpharma

eyeforpharma is a hub for senior-level pharma executives, patient advocacy groups and other health experts to exchange ideas and stay...

Latest intelligence

McCann.jpg
The heart of the matter: Part Two
How is social media impacting publication planning?...
digital numbers
Seven steps to innovating your digital strategy
Dealing with digitally native HCPs...
Online Physician Communities
Online learning increasingly popular for doctors
Sponsorship can help companies raise their profile specific therapy areas...